PR
NASDAQ · PRFX
PainReform Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.95
Down-$0.02 (-2.40%)
Updated Sep 11, 2026, 1:29 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.07M
- P/E ratio
- -0.54
- Dividend yield
- 0.00%
- 52-week range
- $0.91 – $5.39
- Volume
- 36.71K
- Avg. volume
- 332.1K
Price performance
PRFX price history
1M range · 19 trading sessions · Daily adjusted prices
PRFX closed at $0.95 after 19 trading sessions, down 20.81% for the selected period.
- Last close
- $0.95
- Period change
- -20.81%
- Period low
- $0.94
- Period high
- $1.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $0.9831 | $0.9831 | $0.935 | $0.9503 | 36.71K |
| Sep 8, 2026 | $0.99 | $0.99 | $0.93 | $0.945 | 26.62K |
| Sep 4, 2026 | $0.9993 | $0.9997 | $0.927 | $0.968 | 51.28K |
| Sep 3, 2026 | $0.9524 | $1.01 | $0.9207 | $0.9792 | 724.83K |
| Sep 2, 2026 | $0.9359 | $0.979 | $0.9358 | $0.9745 | 26.5K |
| Sep 1, 2026 | $0.9554 | $0.9616 | $0.94 | $0.9512 | 21.26K |
| Aug 31, 2026 | $0.96 | $0.995 | $0.9401 | $0.9536 | 49.34K |
| Aug 28, 2026 | $0.99 | $1.015 | $0.9422 | $0.9611 | 41.97K |
| Aug 27, 2026 | $0.99 | $1.02 | $0.9863 | $0.9868 | 85.49K |
| Aug 26, 2026 | $0.9949 | $0.9949 | $0.95 | $0.9771 | 64.8K |
| Aug 25, 2026 | $1.0304 | $1.05 | $0.9801 | $0.9948 | 48.52K |
| Aug 24, 2026 | $0.9794 | $1.01 | $0.9601 | $1.01 | 49.5K |
| Aug 21, 2026 | $1.00 | $1.05 | $0.9801 | $0.9971 | 67.99K |
| Aug 20, 2026 | $0.9844 | $1.01 | $0.9707 | $1.00 | 53.22K |
| Aug 19, 2026 | $0.9353 | $1.03 | $0.912 | $1.01 | 126.65K |
| Aug 18, 2026 | $0.96 | $0.97 | $0.94 | $0.9417 | 98.75K |
| Aug 17, 2026 | $1.00 | $1.02 | $0.9405 | $0.9702 | 156.76K |
| Aug 14, 2026 | $1.07 | $1.08 | $0.9523 | $1.03 | 353.8K |
| Aug 13, 2026 | $1.03 | $1.20 | $1.01 | $1.20 | 5.55M |
Latest PRFX news
The latest Smart Investors Daily articles mentioning PRFX.
Stock researchResearch & News · Competitors
Loading stock research…
